Back to search
Recurrent Astrocytoma, IDH-Mutant, Grade 3
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Astrocytoma, IDH-Mutant, Grade 3 trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Astrocytoma, IDH-Mutant, Grade 3 trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial…
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or ast…
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (…
This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV gli…
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease. Despite this…